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Abstract
Aims/hypothesis Rapamycin (sirolimus) is one of the primary
immunosuppressants for islet transplantation. Yet there is
evidence that the long-term treatment of islet-transplant
patients with rapamycin may be responsible for subsequent
loss of islet graft function and viability. Therefore, the primary
objective of this study was to elucidate the molecular mecha-
nism of rapamycin toxicity in beta cells.
Methods Experiments were performed on isolated rat and
human islets of Langerhans and MIN6 cells. The effects of
rapamycin and the roles of mammalian target of rapamycin
complex 2 (mTORC2)/protein kinase B (PKB) on beta cell
signalling, function and viability were investigated using
cell viability assays, insulin ELISA assays, kinase assays,
western blotting, pharmacological inhibitors, small interfering
(si)RNA and through the overproduction of a constitutively
active mutant of PKB.
Results Rapamycin treatment of MIN6 cells and islets of
Langerhans resulted in a loss of cell function and viability.
Although rapamycin acutely inhibited mTOR complex 1
(mTORC1), the toxic effects of rapamycin were more close-
ly correlated to the dissociation and inactivation of
mTORC2 and the inhibition of PKB. Indeed, the overpro-
duction of constitutively active PKB protected islets from
rapamycin toxicity whereas the inhibition of PKB led to a
loss of cell viability. Moreover, the selective inactivation of
mTORC2 using siRNA directed towards rapamycin-
insensitive companion of target of rapamycin (RICTOR),
mimicked the toxic effects of chronic rapamycin treatment.
Conclusions/interpretation This report provides evidence
that rapamycin toxicity is mediated by the inactivation of
mTORC2 and the inhibition of PKB and thus reveals the
molecular basis of rapamycin toxicity and the essential role
of mTORC2 in maintaining beta cell function and survival.
Keywords Apoptosis . Beta cell . Diabetes mellitus . GSIS .
Islet . Islet transplantation . mTOR .mTORC2 . PKB .
Rapamycin . RICTOR
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Introduction
Since the publication of the landmark Edmonton study in
2000 [1], use of rapamycin (sirolimus) has been at the
forefront of immunosuppression for islet transplantation.
The employment of rapamycin as the primary immunosup-
pressant in the Edmonton protocol allowed the avoidance of
glucocorticoids and minimisation of calcineurin inhibitors,
both known to be profoundly diabetogenic [1].
Although the initial results of the Edmonton study were
very promising, enthusiasm was tempered when the 5 year
results of the initial cohort of patients were reported, with
only approximately 10% of recipients maintaining insulin
independence [2]. Although the cause of loss of graft function/
viability is poorly understood there is growing evidence that it
is, in part, due to rapamycin toxicity [3–5].
Rapamycin has been shown to have detrimental effects
on the function and survival of murine pancreatic beta cell
lines [4], cultured murine islets [3, 5] and cultured human
islets [4] as well as of a mouse syngeneic islet-transplant
model [5]. In addition, postmortem examination of a patient
with a failed islet graft transplanted under the Edmonton
protocol showed no evidence of autoimmune or alloimmune
damage to the transplanted islets, suggesting the failure was
due to non-immunological causes, including drug toxicity
[6].
Rapamycin exerts its pharmacological actions via inhibi-
tion of the serine/threonine kinase mammalian target of
rapamycin (mTOR) [7]. mTOR exists in two complexes,
mTOR complex 1 (mTORC1) and mTOR complex 2
(mTORC2). Both mTOR complexes contain mTOR, mam-
malian orthologue of lethal with sec thirteen (mLST8), DEP
(dishevelled, egl-10, pleckstrin) domain-containing mTOR
interacting protein (DEPTOR), the newly discovered
58 kDa glucose-regulated protein (GRP58), Tel2 interacting
protein 1 (TTI1), telomere maintenance 2 (TEL2) and Ras
(rat sarcoma)-related C3 botulinum toxin substrate 1
(RAC1) [8]. In addition, mTORC1 contains regulatory-
associated protein of target of rapamycin (RAPTOR) and
pro-rich Akt substrate of 40 kDa (PRAS40), while
mTORC2 contains rapamycin-insensitive companion of
TOR (RICTOR), mammalian stress activated protein kinase
interacting protein 1 (mSIN1) and protein observed with
RICTOR (PROTOR) [7, 8]. mTORC1 is highly sensitive
to rapamycin whereas, in general, mTORC2 is rapamycin
insensitive [9]. However, it has been shown in some cell
types that prolonged rapamycin treatment inhibits mTORC2
assembly [10, 11].
mTORC1 is activated by nutrients, growth factors and
cellular energy levels [7] and plays a key role in the regu-
lation of beta cell size and proliferation [8]. Indeed, beta cell
specific tuberous sclerosis complex-2 (TSC2; an upstream
negative regulator of mTORC1 [12]) knockout mice have
increased beta cell mass due to increased cell size and
proliferation [13, 14]. The effects of mTORC1 on cell size
are likely to be mediated by the activation of ribosomal S6
protein kinase (S6K) 1 and 2, downstream targets of
mTORC1, as S6k1 (also known as Rps6kb1)-knockout mice
[15] and Rps6-knockin mice, with non-phosphorylatable
ribosomal protein S6 (RPS6) [16] have comparatively
smaller beta cells than wild-type mice.
mTORC2 was originally identified as a mediator of actin
cytoskeletal organisation, polarisation and cell migration
[9], and is responsible for the phosphorylation and activation
of several members of the AGC kinase subfamily, including
protein kinase B (PKB, otherwise known as AKT), serum/
glucocorticoid-induced kinase 1 (SGK1), conventional pro-
tein kinase Cs (PKCs) and PKCε [7]. Recently, it has been
reported that beta cell-specific deletion of Rictor in mice (i.e.
beta cell-specific Rictor knockout mice [βRicKO]) results in a
reduction in beta cell mass (due to impaired proliferation but
not changes in cell size or cell death) accompanied by
moderate hyperglycaemia and glucose intolerance [17].
The initial objective of this study was to elucidate the
molecular basis for rapamycin toxicity in islets. This led to
the discovery that rapamycin treatment of beta cells not only
inhibits mTORC1 but also inhibits mTORC2. More impor-
tantly, we provide evidence that the molecular basis of
rapamycin toxicity is through the inactivation of mTORC2
and its impact on PKB activity. These results reveal a
hitherto unknown essential role for mTORC2 in maintaining
beta cell function and viability.
Methods
Reagents Unless otherwise stated, all chemicals and
reagents were purchased from Sigma-Aldrich (St Louis,
MO, USA). FCS was purchased from Invitrogen (Carlsbad,
CA, USA). [γ32P]ATP was purchased from GE Healthcare
(Piscataway, NJ, USA). Rapamycin was purchased from
Calbiochem (Nottingham, UK). Torin1 [18] was kindly
provided by D. Sabatini (Whitehead Institute for Biomedical
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Research, Cambridge, MA, USA). Recombinant adenovirus
producing a myristylated version (constitutively active) of
PKB (AdCaPKB) was purchased from Vector Biolabs
(Philadelphia, PA, USA).
Cell culture and treatments MIN6 cells [19] were used
between passages 20 and 45 at approximately 80% conflu-
ence and grown as previously described [20]. Treatments
were performed as described in the figure legends.
Islet isolation, culture and treatment Pancreatic islets were
isolated from male Sprague–Dawley rats, weighing 200–
250 g, by collagenase digestion and Histopaque density-
gradient centrifugation as previously described [21]. Rat
islets were cultured in RPMI 1640 containing 5.6 mmol/l
glucose, 100 U/ml penicillin and 100 μg/ml streptomycin.
Human islets were isolated from pancreases from heart-
beating deceased human donors following ethical approval
and informed consent from the donors' relatives. Islets were
isolated at the Scottish National Blood Transfusion Service
Islet Isolation Facility, Edinburgh, UK [22], and transported to
Newcastle University in CMRL 1066 (Cellgro, Herndon, VA,
USA), containing 0.5% (wt/vol.) human serum albumin and
5,000 U heparin. Human islets were cultured in CMRL-NCL1
(PAA Laboratories, Yeovil, UK) containing 1% human serum
albumin, 100 U/ml penicillin and 100 μg/ml streptomycin,
prior to experimentation. Following treatment, rat and human
islets were collected by centrifugation for 1 min at 200 g and
lysed in ice-cold lysis buffer.
SDS-PAGE and western blotting SDS-PAGE and western
blotting were performed as described previously [20]. Anti-
mTOR, anti-RAPTOR, anti-RICTOR, anti-PKB, anti-cleaved
caspase 3, anti-RPS6, anti-S6K1, anti-phosphorylated (P)-
PKB Ser473, anti-P-PKB Thr308, anti-P-RPS6 Ser240/244,
anti-P-S6K1 Thr389, anti-P-forkhead box O (FOXO)1/
FOXO3a Thr24/Thr32, anti-P-glycogen synthetase kinase 3
(GSK3)α/β Ser21/9 and anti-P-PKCα Thr638/641 antibodies
used for western blotting were purchased from Cell Signalling
Technologies (Beverly, MA, USA). Anti-glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-
PKCα was purchased from Transduction Laboratories
(Oxford, UK). Anti-mTOR and anti-RICTOR antibodies used
for immunoprecipitation were purchased from the Division of
Signal Transduction Therapy, University of Dundee, UK.
Infection of cell lines with recombinant adenoviruses Adeno-
virus-mediated transduction of cell lines was performed as
previously described [23].
Immunoprecipitation of mTOR and RICTOR For immunopre-
cipitation, MIN6 cells were lysed in 3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate hydrate (CHAPS)
lysis buffer and the mTOR complexes were isolated essen-
tially as described previously [24].
Glucose-stimulated insulin secretion assay Following treat-
ment, islets or MIN6 cells were incubated in KRB supple-
mented with 1 mmol/l glucose for 60 min at 37°C. The
supernatant fractions were collected and the incubation con-
tinued in KRB containing 20 mmol/l glucose for a further
60 min at 37°C. The supernatant fractions were again col-
lected. For MIN6 cells, the cell pellets were lysed in ice-cold
acid/ethanol solution (HCl 1.5% [vol./vol.], ethanol 75%
[vol./vol.] and H2O 23.5% [vol./vol.]) prior to measurement
of cellular insulin content. Insulin concentration in the su-
pernatant fractions or pellets were assayed using an anti-
mouse (for MIN6 cells) or anti-rat (for rat islets) insulin
ELISA kit (DRG Instruments, Marburg, Germany) with
mouse or rat insulin as a standard in accordance with the
manufacturer’s instructions. The absorbance was read at
450 nm on a Novostar plate reader (BMG Labtech, Cary,
NC, USA).
PKB kinase assay MIN6 cells were infected with a recom-
binant adenovirus producing constitutively active PKB as
described above. At 24 h post infection, MIN6 cells were
treated and lysed as described in the figure legends. PKB
was immunoprecipitated from the lysates using anti-PKB
antibody (Millipore, Watford, UK) as per the manufacturer’s
instructions and the activity of PKB determined using Cross-
tide as a substrate peptide (GRPRTSSFAEG; 30 mmol/l;
Millipore) as previously described [25].
Annexin V/propidium iodide staining Following treatment,
the media were removed and kept. The cells were then
incubated in ×1 trypsin/EDTA (0.5%) for 4 min at 37°C.
DMEM was added and the cells gently dispersed by pipet-
ting, combined with the saved media and centrifuged at
200 g for 5 min at room temperature. The media were
discarded and the cell pellets gently resuspended in DMEM
and equilibrated by incubation at 37°C for 30 min. The cells
were pelleted by centrifugation at 200 g for 10 min at room
temperature and the media removed. Annexin V binding
and propidium iodide staining were performed using the
Annexin-V-Fluos staining kit (Roche, Burgess Hill, UK)
as per the manufacturer’s instructions. Quantification of
staining was performed using a FACScan or FACSCalibur
flow cytometer, and CellQuest software (BD Biosciences,
San Jose, CA, USA).
Cell death detection assay Following islet culture and treat-
ment, evaluation of cell death was performed using the Cell
Death Detection ELISAPLUS kit (Roche, Burgess Hill, UK),
as per the manufacturer’s instructions. Absorbance was
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measured at 405 nm against 2,2′-azino-bis(3-ethylbenzo-
thiazoline-6-sulphonic acid) (ABTS) solution and ABTS
stop solution as a blank using a Novostar plate reader
(BMG Labtech, Aylesbury, UK) and the results expressed
in arbitrary units of oligonucleosome-associated histone.
Small interfering RNA transfection of dispersed islets Islets
were dispersed essentially as described by Jonkers et al.
[26]. Small interfering (si)RNA transfection was performed
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions. For Rictor or
Raptor (also known as Rptor) knockdown, the cells were
transfected for 48 h with 200 nmol/l of on-target plus
SMARTpool small interfering RNA (siRNA) against Rictor
(L-087724-00-0005) or Raptor (L-086862-00-0005), re-
spectively. siGENOME non-targeting siRNA (Dharmacon,
Epsom, UK; scrambled), 200 nmol/l, was used as a control.
Quantification and statistical analysis Immunoblot-band
intensities were quantified using the ImageJ (version 1.44)
software. Statistical analyses were performed as indicated in
the figure legends using GraphPad Prism 5.0 (GraphPad
Software, San Diego, CA, USA).
Results
Rapamycin has deleterious effects on MIN6 cell viability
and function To investigate the effects of rapamycin on
pancreatic beta cell viability and function, the clonal pan-
creatic beta cell line MIN6 [19] was incubated with
200 nmol/l rapamycin for up to 72 h (Fig. 1). Flow cytom-
etry of annexin V and propidium iodide stained MIN6 cells
demonstrated that rapamycin caused a significant loss of
viability by 24 h through an increase in apoptosis rather
than necrosis (Fig. 1a–f). In addition, rapamycin caused a
decrease in beta cell size (Fig. 1g, h) and a reduction in both
basal and glucose-stimulated insulin secretion (GSIS;
Fig. 1i). However, there was no significant change in intra-
cellular insulin content, indicating that the effects of rapa-
mycin on GSIS are due to a defect in insulin secretion,
rather than in insulin synthesis (Fig. 1j).
Rapamycin inhibits both mTORC1 and mTORC2 in MIN6
cells and rat- and human-isolated islets of Langerhans In
order to understand the molecular mechanism by which
rapamycin is causing beta cell toxicity, the effects of rapa-
mycin on mTOR signalling were investigated. MIN6 cells
were treated with rapamycin for up to 72 h and, as expected,
rapamycin acutely (within 1 h) inhibited mTORC1 activity
as determined by a decrease in the phosphorylation status of
S6K on Thr389 and RPS6 on Ser240/244 (Fig. 2a). Interest-
ingly, by 24 h of rapamycin treatment, the phosphorylation of
PKB at Ser473, a downstream target of mTORC2 [27], was
also significantly inhibited, yet total PKB levels were unaf-
fected (Fig. 2a). Moreover, prolonged rapamycin treatment
(48–72 h) also inhibited the turn motif phosphorylation of
PKCα and βII on Thr638/641, which is also mediated by
mTORC2 [28, 29]. Incubation of MIN6 cells with as little as
10 nmol/l rapamycin for 24 h was sufficient to inhibit both
mTORC1 and mTORC2 activity as determined by the phos-
phorylation state of RPS6 on Ser240/244 and PKB on Ser473
(Fig. 2b). This concentration is similar to that seen in the portal
venous system of islet-transplant recipients [30]. These results
clearly indicate that rapamycin inhibits both mTORC1 and
mTORC2 in MIN6 cells.
Given that MIN6 cells are a clonal beta cell line, it was
important to confirm these findings in primary cells. There-
fore, isolated rat and human islets of Langerhans were
treated with 200 nmol/l rapamycin for 48 and 72 h and the
activities of mTORC1 and mTORC2 were determined by
assessing the phosphorylation states of RPS6 on Ser240/244
and PKB on Ser473. Rapamycin treatment resulted in the
inhibition of both RPS6 on Ser240/244 and PKB on Ser473,
indicating that rapamycin also inhibits mTORC1 and
mTORC2 in rat (Fig. 2c) and human islets of Langerhans
(Fig. 2d). Rapamycin, 200 nmol/l, was used in these experi-
ments and subsequent experiments to produce maximal
effects. However, lower doses of rapamycin inhibit
mTORC2 and cause cell death in rat islets of Langerhans
(see electronic supplementary material [ESM] Fig. 1).
Rapamycin inhibits mTORC2 through the dissociation of the
mTORC2 complex The inhibition of mTORC2 by rapamy-
cin could be via a reduction in the levels of mTORC2
components or the dissociation of the complex. However,
treatment of MIN6 cells with rapamycin for up to 72 h
caused no reduction in the levels of either mTOR or RICTOR,
the principal components of mTORC2 (Figs 2a and 3). Isola-
tion of mTORC1 and mTORC2 complexes by immunopre-
cipitation with anti-mTOR antibodies followed by analysis
revealed that prolonged rapamycin treatment caused the dis-
sociation of both RAPTOR and RICTOR from mTOR, indi-
cating that rapamycin causes the dissociation of both
mTORC1 and mTORC2 (Fig. 3). Moreover, isolation of the
mTORC2 by immunoprecipitation with anti-RICTOR anti-
bodies followed by analysis of its components confirmed that
prolonged rapamycin treatment caused the dissociation of
mTOR from RICTOR (Fig. 3). Therefore, rapamycin inhibits
mTORC2 in beta cells by causing its dissociation.
PKB is essential for cell survival and constitutively active
PKB protects MIN6 cells and rat islets from the deleterious
effects of rapamycin PKB is an important pro-survival fac-
tor and, as rapamycin causes a decrease in PKB phosphor-
ylation and a decline in cell survival, we further explored the
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effects of rapamycin on the phosphorylation and activation
of PKB. Treatment of MIN6 cells with rapamycin for 24 h
resulted in a significant decrease in the PKB phosphoryla-
tion at Ser473 but not at Thr308, as well as a significant
decrease in its activity (Fig. 4a). This decrease in PKB activity
was coincident with an increase in the cleaved form of
caspase-3, a cellular marker of apoptosis (Fig. 4a). Moreover,
the inhibition of PKB activity results in an increase in apopto-
sis and a decrease in function in both MIN6 cells and rat islets
(ESM Fig. 2).
To determine whether the loss of PKB activity was respon-
sible for rapamycin toxicity, MIN6 cells were infected with an
adenovirus producing a myristylated version (constitutively
active) of PKB (AdCaPKB), which directs PKB to the plasma
membrane and thus confers a constitutively active phenotype
[31]. In cells overproducing AdCaPKB, prolonged rapamycin
treatment had no detectable effect on PKB kinase activity or
on the phosphorylation of the PKB substrate GSK3 (Fig. 4b).
Moreover, producing AdCaPKB had no effect on the ability of
rapamycin to inhibit the phosphorylation of RPS6 on Ser240/
244 and hence mTORC1 (Fig. 4b). Importantly, the produc-
tion of AdCaPKB in MIN6 cells was found to protect cells
from the negative effects of prolonged rapamycin treatment on
viability (Fig. 4c) and GSIS (Fig. 4d). To confirm these find-
ings in primary cells, rat islet of Langerhans were infected
with AdCaPKB and the effects of rapamycin on islet function
and viability were compared with mock-infected islets. Rapa-
mycin treatment for 48 h resulted in increased cell death in
both infected and uninfected islets. However, cell death was
significantly attenuated in islets infectedwith AdCaPKB com-
pared with mock-infected islets (Fig. 4e). Rapamycin treat-
ment for 72 h resulted in a significant reduction in GSIS
(Fig. 4f). Importantly, islets infected with AdCaPKB were
fully protected against the effects of rapamycin on GSIS
(Fig. 4f). Therefore, the deleterious effects of rapamycin on
beta cell viability and function are likely to be caused by the
inhibition of PKB mediated by the inactivation of mTORC2.
Evidence that inhibition of mTORC2 is primarily responsible
for rapamycin toxicity To provide supportive evidence that
mTORC2 plays a critical role in beta cell survival and
function, isolated rat islets of Langerhans were treated for up
to 24 h with rapamycin or Torin1, a novel selective mTOR
inhibitor that, unlike rapamycin, rapidly inhibits both
mTORC1 and mTORC2 [18] (Fig. 5). Torin1 had inhibited
both mTORC1 and mTORC2 by 8 h as determined by the
a
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Fig. 1 Rapamycin has deleterious effects on MIN6 cell viability and
function. MIN6 cells were treated with 200 nmol/l rapamycin as
indicated. a, b Rapamycin decreases viability. Following treatment,
cells were dispersed, stained with annexin Vand propidium iodide, and
then analysed by flow cytometry: y-axis (FL1-H), propidium iodide; x-
axis (FL2-H), annexin V. Representative histograms of control cells (a)
and cells treated with rapamycin (b) for 24 h are shown. c Quantifica-
tion of percentage of apoptotic cells was performed by flow cytometry.
p values were obtained using a one-way ANOVA with Dunnett’s test.
d, e Representative histograms of cell cycle distribution. MIN6 cells
were treated with vehicle (100% ethanol; d) or 200 nmol/l rapamycin
(e) for 24 h, and then analysed by flow cytometry. f The percentage of
cells in subG1, G0/G1, S and G2/M phases related to the total cell
population were quantified. p values were obtained using a two-way
ANOVA with Bonferroni post test. Without rapamycin: white, subG1,
10.3±0.6; light grey, G0/G1, 66.5±1.3; dark grey, S, 8.5±0.3; and
black, G2/M, 14.9±1.3. With rapamycin: white, subG1, 41.8±1.5; light
grey, G0/G1, 44.4±2.1; dark grey, S, 8.5±0.8; and black, G2/M, 5.3±
0.2. g Rapamycin caused a decrease in cell size. The histogram (FSC-H)
for the G0/G1 population shows a left-ward shift in response to rapamycin
treatment compared with control, demonstrating that rapamycin causes a
decrease in cell size. h Quantification of data from (g). Data were
expressed as percentage of control. p values were obtained by paired
Student’s t test. i Rapamycin inhibits GSIS. Following rapamycin treat-
ment, cells were incubated in KRB containing 1 mmol/l glucose for 1 h
followed by KRB containing 20 mmol/l glucose for a further 1 h. Super-
natant fractions were collected and assayed for insulin concentration
using ELISA. p values were obtained using a one-way ANOVA followed
by Bonferroni post-test. For simplicity, not all statistical significances are
shown. j Cells from (i) were lysed and insulin content determined by
ELISA. p values were obtained using Dunnett’s test with one-way
ANOVA. All data are displayed as means±SE, n03. **p00.001–0.01,
***p<0.001. Results shown are representative of at least three indepen-
dent experiments. Rap, rapamycin
R
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phosphorylation state of RPS6 and PKB on Ser473, respec-
tively (Fig. 5a). Torin1 or rapamycin had no effect on the
phosphorylation of PKB at Thr308. Torin1 also caused a rapid
increase in the rate of apoptosis (Fig. 5b), and a decrease in
GSIS (Fig. 5c). Compared with islets treated with Torin1, the
inhibitory effects of rapamycin on mTORC2 and PKB were
delayed (Fig. 5a). Moreover, the rate of cell death was accel-
erated in Torin1-treated cells compared with rapamycin-
treated cells (Fig. 5b). Therefore, it is the inhibition of
mTORC2, rather than mTORC1, that correlates with de-
creased viability and function. To provide further evidence
to support these findings mTORC1 function was inhibited in
primary rat islets of Langerhans by knocking down Raptor
expression using siRNA (Fig. 5d–f). This had no significant
effect on either islet viability (Fig. 5e) or GSIS (Fig. 5f), yet
led to a significant decrease in the phosphorylation of S6K1
and RPS6 (Fig. 5d).
Downregulation of Rictor expression causes a loss of islet of
Langerhans viability As mTORC2 is required for full PKB
activation and PKB protects cells against rapamycin toxic-
ity, we aimed to determine whether there was a causal link
between the inhibition of mTORC2, the inactivation of PKB
and the loss of islet viability. To investigate this, mTORC2
activity was downregulated in dispersed islets of Langerhans
by knocking down Rictor expression using siRNA. siRNA-
mediated knockdown of Rictor led to a decrease in the phos-
phorylation of PKB on Ser473, indicative of decreased
mTORC2 activity, without affecting the phosphorylation of
RPS6, a marker of mTORC1 activity (Fig. 6a). This correlated
with an increase in apoptosis (Fig. 6b) and a decrease in GSIS
(Fig. 6c). Importantly, there was no significant change in the
phosphorylation of PKB on Thr308 in islets transfected with
Rictor siRNA (Fig. 6a; see discussion). Taken together, these
results indicate that mTORC2 is essential for beta cell
viability.
Discussion
Rapamycin has been used as the primary immunosuppres-
sant in many islet-transplant programmes over the last de-
cade [1]. This choice has been based on the assumption that
rapamycin is less toxic to pancreatic beta cells than other
immunosuppressants, such as corticosteroids and tacroli-
mus. However, rapamycin and its analogues can cause
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deleterious effects on beta cell mass and islet engraftment
[3–5], primarily through induction of beta cell apoptosis.
Prior to this study, the molecular basis for this toxicity had
not been known.
Although rapamycin is known to inhibit mTORC1 in
beta cells, we show that prolonged rapamycin treatment is
able to abolish the activity of mTORC2 in MIN6 cells, rat
and human islets of Langerhans as demonstrated by either a
decrease in the phosphorylation of its downstream target
PKB on Ser473 (Fig. 2) and/or a reduction in PKB kinase
activity (Fig. 4a). Inhibition of PKB using PKB (Akt) in-
hibitor (AKTi) also results in the loss of cell viability (ESM
Fig. 2), whereas the overproduction of constitutively active
PKB rescues MIN6 cells or islets from rapamycin-induced
apoptosis (Fig. 4). This is not specifically mediated by the
recovery of PKB Ser473 phosphorylation but through an
increase in overall PKB activity.
Unlike rapamycin, Torin1 and AKTi rapidly inhibit PKB
phosphorylation at Ser473, and also lead to a more rapid
loss in beta cell viability compared with rapamycin (Fig. 5
and ESM Fig. 2). Moreover, the inactivation of mTORC2 by
knockdown of Rictor expression in rat islets causes an
increase in apoptosis to a similar extent as rapamycin
(Fig. 6b), whereas the inactivation of mTORC1 by knock-
down of Raptor expression had no significant effect on cell
viability (Fig. 5d,e). Therefore, we conclude that the main-
tenance of mTORC2 activity is critical for beta cell survival
and that the inhibition of mTORC2 by rapamycin is likely to
be responsible for rapamycin toxicity to pancreatic islets.
Yet it was recently reported that βRicKO mice, with beta
cell-specific ablation of Rictor, do not show an increase in
beta cell death, although there is a reduction in islet mass
and function [17]. One possible explanation for this appar-
ent contradiction is that although PKB phosphorylation at
Ser473 is compromised in the islets isolated from βRicKO
mice, the phosphorylation of PKB at Thr308, which is
mediated by phosphoinositide-dependent kinase 1 (PDK1)
[32], is enhanced [17]. This is likely to have a compensatory
effect on the activity of PKB. However, the overall kinase
activity of PKB in islets from βRicKO mice was not
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Fig. 4 PKB is indispensable for beta cell survival and the overpro-
duction of constitutively active PKB protects MIN6 cells from the
deleterious effects of rapamycin. a, b PKB in vitro activity assay.
MIN6 cells were incubated in DMEM supplemented with 15%
(vol./vol.) FCS in the absence or presence of rapamycin (200 nmol/l) for
72 h. Endogenous PKB was immunoprecipitated from the lysates and
subjected to PKB kinase assay. Lysates previous to PKB kinase assay
were collected and separated by SDS-PAGE. Proteins were resolved on
SDS-PAGE and immunoblotted using antisera against P-PKB Ser473, P-
PKB Thr308, P-RPS6 Ser240/Ser244, P-GSK3α/β Ser21/Ser9, total
PKB, RPS6 and cleaved caspase 3. Following cell lysis, PKB was
immunoprecipitated using immobilised antibody and kinase activity de-
termined using [γP32]ATP and crosstide as the substrate. p values were
obtained using a one-way ANOVAwith Bonferroni post-test. b–dMIN6
cells were mock infected or infected with adenovirus producing consti-
tutively active PKB (AdCaPKB) at a multiplicity of infection of 500 for
24 h, followed by incubation for 72 h (b) or 24 h (c, d) in the presence or
absence of 200 nmol/l rapamycin. c Following treatment, cells were
dispersed, stained with annexin V and propidium iodide, and then ana-
lysed by flow cytometry. The percentage of apoptotic cells was quanti-
fied. p values were obtained using a one-way ANOVAwith Bonferroni
post-test. d Following rapamycin treatment, cells were incubated in KRB
containing 1 mmol/l glucose for 1 h, followed by incubation in KRB
containing 20mmol/l glucose for a further 1 h. Supernatant fractions were
collected and assayed for insulin concentration using ELISA. Results are
expressed as fold change of stimulated insulin secretion over basal insulin
secretion. p values were obtained using a one-way ANOVAwith Bonfer-
roni post-test. All immunoblots are representative of three independent
experiments. e, f Rat islets were infected with adenovirus producing
constitutively active PKB for 24 h, followed by a further 48 h incubation
in the presence or absence of 200 nmol/l rapamycin. e To determine the
rate of cell death, internucleosomal DNA fragmentation was analysed. p
values were obtained using a one-way ANOVA followed by Bonferroni
post-test. f Following rapamycin treatment, islets were incubated in KRB
containing 1 mmol/l glucose for 1 h followed by a further 1 h incubation
in KRB containing 20 mmol/l glucose. Supernatant fractions were col-
lected and assayed for insulin concentration using ELISA. p values were
obtained using a one-way ANOVA followed by Tukey’s multiple com-
parison test. For simplicity, not all statistical significances are shown. All
data are shown as means±SE, n03. *p00.05–0.01, **p00.01–0.001 and
***p<0.001. All immunoblots are representative of three independent
experiments. Cl. casp 3, cleaved caspase 3; Rap, rapamycin
R
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reported by Gu et al. [17]. In contrast, we have been unable
to detect any significant increase in the phosphorylation of
PKB at Thr308 in rat islets in which Rictor expression was
acutely knocked down (Fig. 6a) or in islets in which
mTORC2 activity was inhibited by either rapamycin or
Torin1 (Figs 5a and 6a). Therefore, it is plausible that in
βRicKO mice, signalling events downstream of PKB
Thr308 phosphorylation rescue beta cells from apoptosis.
PKB integrates upstream survival signals to maintain beta
cell viability. It protects beta cells from streptozotocin-induced
cell death and mediates the anti-apoptotic actions of insulin,
IGF1 and glucagon-like peptide 1 (GLP-1; reviewed in Xie et
al. and Elghazi et al. [8, 33]). Of note, mice with knockout of
Pkbβ (also known as Akt2), unlike those with knockout of
Pkbα (also known as Akt1) [34], have a decrease in beta cell
mass that parallels an increase in beta cell apoptosis [35].
Interestingly, it has recently been reported that the inhibition
of PKB phosphorylation on Ser473 by rapamycin in primary
rat and human platelets correlates with a decrease in the
activity of PKBβ rather than PKBα [36], Therefore, it is
tempting to speculate that rapamycin islet toxicity is caused
by the specific impairment of PKBβ activity via the loss of
Ser473 phosphorylation caused by the inactivation of
mTORC2. Moreover, decreases in PKB phosphorylation in
transgenic mice where components of the IRS–PDK1 path-
way are ablated (reviewed in Elghazi et al. [33]), or mice
producing constitutively active S6K in which IRS signalling
is impaired [37], correlate with decreased viability. These anti-
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Fig. 5 Torin1 causes a reduction in the viability and function of islets
of Langerhans. a Rat islets were treated with rapamycin (200 nmol/l) or
Torin1 (200 nmol/l) for the times indicated. b Rat islets were treated as
in (a), and internucleosomal DNA fragmentation was determined as an
indicator of cell apoptosis using the cell death detection ELISA. p
values were obtained using a two-way ANOVA followed by Bonfer-
roni post-test comparing rapamycin- and Torin1-treated samples. Black
circles, control; white squares, rapamycin; black triangles, Torin1. c
Rat islets were treated with rapamycin (200 nmol/l) or Torin1
(200 nmol/l) for 40 h, and then incubated in KRB containing
1 mmol/l glucose for 1 h followed by a further 1 h incubation in
KRB containing 20 mmol/l glucose. Supernatant fractions were col-
lected and assayed for insulin concentration using ELISA. p values
were obtained using a one-way ANOVA followed by Bonferroni post-
test. d Dispersed rat islets were transfected with scrambled or Raptor
siRNAs for 24 h and then incubated for 48 h in the presence or absence
of rapamycin (200 nmol/l). For (a) and (d), after cell lysis, proteins
were separated on SDS-PAGE and western blotted using antisera
against RAPTOR, P-PKB Ser473, P-S6K1 Thr389, P-RPS6 Ser240/
Ser244, PKB and RPS6. e Dispersed rat islets were transfected with
scrambled or Raptor siRNAs for 24 h prior and then further incubated
for 48 h in the presence or absence of rapamycin (200 nmol/l). Apo-
ptosis was determined by measuring using the cell death detection
ELISA. p values were obtained using two-way ANOVA followed by
Bonferroni post-test comparing each column with the first column
(siRNA Scr); n03. f Rat islets were transfected and treated as in (e),
and then incubated in KRB containing 1 mmol/l glucose for 1 h
followed by a further 1 h incubation in KRB containing 20 mmol/
l glucose. Supernatant fractions were collected and assayed for insulin
concentration using an ELISA. p values were obtained using one-way
ANOVA followed by Tukey’s multiple comparison test, n03. All data
are shown as means±SE. *p00.05–0.01, **p00.01–0.001 and ***p<
0.001. All immunoblots are representative of three independent experi-
ments. Rap, rapamycin; Scr, scrambled
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apoptotic effects of PKB may be mediated by the nuclear
exclusion and degradation of the FOXO family of proteins,
which is controlled by the phosphorylation of PKB on Ser473
[38]. However, rapamycin was unable to inhibit the phosphor-
ylation of FOXO (ESM Fig. 3), and mTORC2 ablation in beta
cells from βRicKO mice leads to an increase in protein
production of FOXO1 and its nuclear retention, yet it does
not result in an increase in apoptosis [17]. Therefore, it is
likely that the positive role of PKB in beta cell viability is
mediated by other downstream targets implicated in cell
survival, such as B cell CLL/lymphoma 2 (BCL-2) family
members, pro-caspase-9 and murine double minute 2
(MDM2) (reviewed in Hers et al. [39]).
We, in this report, and others have shown that long-term
rapamycin treatment inhibits GSIS [3–5]. However, GSIS is
not affected by short-term rapamycin treatment [3, 40, 41] and
is unaffected byRaptor knockdown (Fig. 5f), indicating that the
deleterious effects of rapamycin on GSIS are not mediated
through the inhibition of mTORC1 but caused by the inhibition
of mTORC2. Although mTORC1 regulates protein synthesis,
rapamycin has little effect on either insulin synthesis [42] or
insulin content (Fig. 1j and [43]) in vitro. Yet the chronic
inhibition of mTORC1 in vivo may lead to decreased insulin
content which, in turn, could impact on GSIS. However, the
inhibition of GSIS by rapamycin has been reported to be
caused by reduced mitochondrial ATP production [43].
The findings of this study have important implications for
clinical islet transplantation. First, it brings into question the
use of rapamycin as a primary immunosuppressant in islet
transplantation. However, there are limited alternatives as
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Fig. 6 siRNA knockdown of Rictor expression causes a loss of beta
cell viability. a Dispersed rat islets were transfected with scrambled or
Rictor siRNAs for 24 h and then incubated for 48 h in the presence or
absence of rapamycin (200 nmol/l). Cells were then lysed, proteins
were resolved on SDS-PAGE and western blotted using antisera
against RICTOR, RAPTOR, P-PKB Ser473, P-PKB Thr308, P-RPS6
Ser240/Ser244, PKB and RPS6. Levels of P-PKB Ser473, P-PKB
Thr308 and P-RPS6 Ser240/244 were quantified by densitometry and
expressed as percentage of control (scrambled siRNA). p values were
obtained using one-way ANOVA followed by Bonferroni post-test. b
Dispersed rat islets were transfected with a scrambled siRNA or Rictor
siRNA for 24 h and then incubated for 48 h in the presence or absence
of rapamycin (200 nmol/l). Apoptosis was determined using the cell
death detection ELISA (see Methods) following manufacturer’s
instructions. p values were obtained using two-way ANOVA followed
by Bonferroni post-test comparing each column to the first column
(siRNA Scr); n04. c Rat islets were transfected and treated as in (a),
and then incubated in KRB containing 1 mmol/l glucose for 1 h
followed by a further 1 h incubation in KRB containing 20 mmol/
l glucose. Supernatant fractions were collected and assayed for insulin
concentration using ELISA. p values were obtained using one-way
ANOVA followed by Tukey’s multiple comparison test, n03. All data
are shown as means±SE. *p00.05–0.01, **p00.01–0.001 and ***p<
0.001. Results from (a) are from five independent experiments; immu-
noblots from one representative experiment are shown. Results from
(b) and (c) are from three independent experiments. Rap, rapamycin;
RIC, RICTOR; Scr, scrambled
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glucocorticoids and tacrolimus have more significant det-
rimental effects on beta cells. An alternative is mycophe-
nolate mofetil (MMF); however, studies on human islets
have shown that MMF treatment results in a significant
reduction in GSIS [41]. The key role of mTORC2 and
PKB in beta cell function and survival (this report and
others [44–48]) is of importance to those involved in the
development of novel immunosuppressive agents for islet
transplantation. Ideally, any new agents should not affect
PKB activity. One potential area for development is
mTORC1-specific inhibitors, which should retain the im-
munosuppressive effects of rapamycin without any
mTORC2-mediated toxicity. However, this makes the as-
sumption that the immunosuppressive effects of rapamycin
are indeed mediated solely via mTORC1 rather than
mTORC2. In addition, the in vivo activation of PKB might
improve the outcome of islet transplantation by improving the
function and survival of transplanted beta cells.
In conclusion, we have shown that the molecular
basis of rapamycin-induced islet toxicity is through the
dissociation and inhibition of mTORC2 and the subse-
quent reduction in PKB phosphorylation at Ser473 and
the suppression of its kinase activity. As a consequence,
this work has revealed an important role for mTORC2
in beta cell survival.
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